Most dry-eye symptoms result from an abnormal, nonlubricative ocular surface that increases shear forces under the eyelids and diminishes the ability of the ocular surface to respond to environmental challenges. This ocular-surface dysfunction may result from immunocompromise due to systemic autoimmune disease or may occur locally from a decrease in systemic androgen support to the lacrimal gland as seen in aging, most frequently in the menopausal female.
Components of the ocular surface (cornea, conjunctiva, accessory lacrimal glands, and meibomian glands), the main lacrimal gland, and interconnecting innervation act as a functional unit. When one portion is compromised, normal lacrimal support of the ocular surface is impaired. Resulting immune-based inflammation can lead to lacrimal gland and neural dysfunction. This progression yields the OS symptoms associated with dry eye.
Restoration of lacrimal function involves resolution of lymphocytic activation and inflammation. This has been demonstrated in the MRL/lpr mouse using systemic androgens or cyclosporine and in the dry-eye dog using topical cyclosporine. The efficacy of cyclosporine may be due to its immunomodulatory and antiinflammatory (phosphatase inhibitory capability) functions on the ocular surface, resulting in a normalization of nerve traffic.
Although the etiologies of dry eye are varied, common to all ocular-surface disease is an underlying cytokine/receptor-mediated inflammatory process. By treating this process, it may be possible to normalize the ocular surface/lacrimal neural reflex and facilitate ocular surface healing.
From Allergan, Irvine, California (M.E.S., J.G.), LSU Eye Center, New Orleans, Louisiana (R.W.B.), Scripps Research Foundation, La Jolla, California (R.I.F.), University of Southern California, Los Angeles, California (A.K.M.), University of Miami, Miami, Florida (S.C.P.), U.S.A.
Address correspondence and reprint requests to Dr. M.E. Stern, Department of Biological Sciences, Allergan, Inc., 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534, U.S.A. E-mail: firstname.lastname@example.org
Submitted January 16, 1998. Revision received May 29, 1998. Accepted June 3, 1998.